Event Brief
Sep 4, 2026 at 12:00 PM ET
Pancreatic cancer drug shows early lung cancer promise
By The BriefBrief
An early-phase trial tested daraxonrasib, a pill approved for advanced pancreatic cancer, in 136 patients with non-small cell lung cancer. The drug was reported safe and reduced tumor burden in more than 30% of patients with RAS-protein mutations, according to a study published Wednesday in the New England Journal of Medicine.
WHO: Researchers and 136 patients with non-small cell lung cancer; study authors published in the New England Journal of Medicine
WHAT: Early clinical trial results suggest daraxonrasib may reduce tumors in a subset of non-small cell lung cancer patients with RAS-protein mutations.
WHEN: Reported Sep 4, 2026 at 11:01 AM ET
WHERE: CA
WHY: Cause not yet established.
Reporting from 1 identified publisher for this event.
View all 1 publishers
Publishers represented across this event arc
These publishers contributed reporting to the broader event history. Not every source addresses the specific development described above.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
County readies El Niño response for heavy rains
El Nino
Sep 4, 2026 at 12:00 PM ET
John Boston revisits the art of postcards
Local Column
Sep 4, 2026 at 12:00 PM ET
Pasco FDOT Road Work to Shift Lanes Sept. 6–12
Fdot
Sep 4, 2026 at 12:00 PM ET
Pinellas DUI “Wolf Pack” crackdown this weekend
Dui
Sep 4, 2026 at 12:00 PM ET
